REGENERON PHARMACEUTICALS (REGN)
US75886F1075 - Common Stock
REGENERON PHARMACEUTICALS
NASDAQ:REGN (11/21/2024, 4:35:16 PM)
After market: 744.5 0 (0%)744.5
+1.15 (+0.15%)
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 13,450 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591
P: 17813705000
CEO: Leonard S. Schleifer
Employees: 13926
Website: https://www.regeneron.com/
REGN News
2 days ago - ChartmillWhat's going on in today's session: S&P500 moversCurious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
7 days ago - Regeneron Pharmaceuticals, Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)7 days ago - Regeneron Pharmaceuticals, Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer...
7 days ago - The Motley Fool2 Top Growth Stocks to Buy on the DipTheir recent issues are nothing to fret over for investors focused on the long game.
8 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH8 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASHOral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal...
REGN Twits
Here you can normally see the latest stock twits on REGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
